Celcuity (FRA:7VR) 5-Year EBITDA Growth Rate: -23.40% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7VR Celcuity Inc FRA:7VR
30 GF Score
Price €93.50
! 2 Warning Signs
View Full Analysis

What is Celcuity 5-Year EBITDA Growth Rate?

Celcuity FRA:7VR 30 5-Year EBITDA Growth Rate is -23.40% as of Mar. 2026. GuruFocus rates FRA:7VR with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Celcuity's EBITDA per Share for the three months ended in Mar. 2026 was €-0.74.

During the past 3 years, the average EBITDA Per Share Growth Rate was -11.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -23.40% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -25.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Celcuity was -5.10% per year. The lowest was -53.20% per year. And the median was -19.80% per year.

Celcuity  (FRA:7VR) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Celcuity 5-Year EBITDA Growth Rate Related Terms

FRA:7VR vs RLAY, VKTX, DYN: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Celcuity's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celcuity 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celcuity's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Celcuity's 5-Year EBITDA Growth Rate falls into.


FRA:7VR
30GF Score
Celcuity Inc FRA:7VR
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celcuity 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of -23.40% mean?
Celcuity (FRA:7VR) has a 5-Year EBITDA Growth Rate of -23.40% as of Mar. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Celcuity and its competitors.
Is Celcuity's 5-Year EBITDA Growth Rate too high?
Celcuity's current 5-Year EBITDA Growth Rate is -23.40%. Overall, Celcuity has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Celcuity's 5-Year EBITDA Growth Rate compare to RLAY and VKTX?
Celcuity's 5-Year EBITDA Growth Rate of -23.40% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Celcuity and its competitors. Celcuity's current 5-Year EBITDA Growth Rate is -23.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celcuity stock overvalued right now?
Celcuity (FRA:7VR) has a current 5-Year EBITDA Growth Rate of -23.40%. The current 5-Year EBITDA Growth Rate is -23.40%. Celcuity's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Celcuity (FRA:7VR), the current 5-Year EBITDA Growth Rate is -23.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Celcuity Business Description

Other Exchanges CELC:USA
Address 16305 36th Avenue North, Suite 100, Minneapolis, MN, USA, 55446
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
30GF Score

Get the complete analysis for FRA:7VR

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€93.50
Price